Objective: This study endeavors to understand the intricate pathophysiological interactions among concurrent manifestations of cauda equina syndrome, Parkinson’s Disease (PD), and depression, with the objective of formulating advanced, nuanced therapeutic strategies. The focus is on delineating the distinct yet overlapping neurobiological mechanisms at play, aiming to bridge gaps in current treatment methodologies and enhance patient-specific care.

Background: The concurrent manifestation of cauda equina syndrome, PD, and depression in a patient presents a complex and multifaceted neuropathological challenge, pushing the boundaries of conventional treatment approaches.

Method: Utilizing thorough literature review, our investigation delved into the multi-dimensional impacts of these conditions, examining motor dysfunction, autonomic irregularities, neurochemical dynamics, and psychological manifestations.

Results: The research highlighted a compounded motor function impairment, where PD’s characteristic dopaminergic neuron degeneration in the substantia nigra aggravates the motor limitations imposed by cauda equina syndrome. This results in a marked reduction in patient mobility and independence. Moreover, this study found that bladder dysfunction, a hallmark of cauda equina syndrome, is significantly worsened by PD’s autonomic dysregulation, leading to acute incontinence issues. Our findings also suggest that depressive states in PD are intricately linked to the disease’s pathophysiology, not merely a psychological response. This depression is further deepened by the chronic pain and physical limitations of cauda equina syndrome. The investigation uncovered a notable increase in apathy and amotivation, driven by overlapping dopamine and serotonin pathway dysfunctions in both PD and depression, compounded by the physical constraints of cauda equina syndrome.

Conclusion: Our study underscores the necessity of an integrated, multifaceted treatment regimen. This involves combining neurological and psychiatric care via physical and occupational therapies, carefully adjusted pharmacological treatments, and comprehensive psychotherapy. Lifestyle interventions and strengthening patient support systems are also pivotal. This comprehensive approach is instrumental in mitigating the compounded challenges posed by this triad, aiming to substantially improve patient outcomes and quality of life.

References: 1. LoRusso S. Disorders of the Cauda Equina. CONTINUUM: Lifelong Learning in Neurology. 2021;27(1):205-224. doi:https://doi.org/10.1212/con.0000000000000903
2. Long B, Koyfman A, Gottlieb M. Evaluation and management of cauda equina syndrome in the emergency department. The American Journal of Emergency Medicine. 2020;38(1):143-148. doi:https://doi.org/10.1016/j.ajem.2019.158402
3. Gibson LL, Harborow L, Nicholson T, Bell D, David AS. Is scan‐negative cauda equina syndrome a functional neurological disorder? A pilot study. European Journal of Neurology. 2020;27(7):1336-1342. doi:https://doi.org/10.1111/ene.14182
4. Rahul Rahangdale, Rana S, Prakash P, et al. Glioneuronal Growth Infiltrating Lumbosacral Nerve Roots Following Intrathecal Stem Cell Injections Highlighting Perils of Stem Cell Tourism. Movement Disorders Clinical Practice. 2019;6(4):324-326. doi:https://doi.org/10.1002/mdc3.12741
5. Hassan Q, Li S, Ferrag C, Kerman K. Electrochemical biosensors for the detection and study of α-synuclein related to Parkinson’s disease – A review. Analytica Chimica Acta. 2019;1089:32-39. doi:https://doi.org/10.1016/j.aca.2019.09.013

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/neuropathological-synergy-in-cauda-equina-syndrome-parkinsons-disease-and-depression-breaking-the-dysphoric-cycle/